Endocrine Abstracts

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

Introduction: Escalated doses of octreotide LAR are commonly used to control functional symptoms and/or tumour growth, but there is limited evidence regarding the efficacy of this approach.Methods: Retrospective analysis of 69 NET patients treated with octreotide LAR 30 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change in symptomatology and biomarker levels was considered significant....

Background: Gastrointestinal (GI) neuroendocrine tumours (NETs) are potentially malignant lesions originating from the enterochromaffin cells of the GI tract. These neoplasms often produce characteristic hormonal syndromes and can cause debilitating symptoms. Endoscopic submucosal dissection (ESD) is a well-established, complex, endoscopic technique, which allows for full resection of the mucosal and submucosal lesions without the need for open surgery.M...

Background: Although small bowel (SB) neuroendocrine tumours (SBNETs) often present as indolent lesions, late diagnosis may result in poor outcomes. Successful management is therefore dependent on early identification. Double-balloon enteroscopy (DBE) enables direct SB mucosal visualisation, sampling and endotherapy. Our aim was to evaluate the role of DBE for early diagnosis and management of SBNETs.Methods: Retrospective review of all SBNETs diagnosed/...

Introduction: To prevent loco-regional recurrence and subsequent development of distant metastases in Appendiceal Neuro-Endocrine Neoplasms (ANEN), the existing Guidelines have suggested several criteria for a prophylactic right hemicolectomy, following the initial appendectomy. However, some of those criteria seem rather arbitrary and have not been validated by large studies.Aim: To assess the outcomes of prophylactic right hemicolectomy (RHC), focusing...

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...